Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis

Annals of Pharmacotherapy

Volumn 39, Issue 3, 2005, Pages 427-432

  Stein, Gary E ^a,c   Schooley, Sharon L ^a   Peloquin, Charles A ^b   Kak, Vivek ^c   Havlichek, Daniel H ^a   Citron, Diane M ^d   Tyrrell, Kerin L ^d   Goldstein, Ellie J C ^d  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d RM Alden Research Laboratory ^*  (United States)

Author keywords

Linezolid; Obesity; Pharmacodynamics; Pharmacokinetics

Indexed keywords

LINEZOLID;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; CELLULITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; ENTEROCOCCUS FAECIUM; FEMALE; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; OBESITY; PEPTOSTREPTOCOCCUS; PHARMACODYNAMICS; PRIORITY JOURNAL; SOFT TISSUE INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CELLULITIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HALF-LIFE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OBESITY; OXAZOLIDINONES; SERUM BACTERICIDAL TEST; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 13944269434     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E484     Document Type: Article

References (37)

1. Harbarth S, Albrich W, Goldman DA, Huebner J. Control of multiply resistant cocci: do international comparisons help? Lancet Infect Dis 2001; 1:251-61.
2. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahn DF, Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003;22:406-19.
3. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, et al. Comparison of community- and healthcare-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290: 2976-84.
4. Said-Salim B, Mathema B, Kreiswirth BN. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol 2003;24:451-5.
5. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003;36:473-81.
6. Richter SS, Kealey DE, Murray CT, Heilmann KP, Coffman SL, Doern GV. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2003;52:123-7.
7. Stalker DJ, Jingbluth GL, Hopkins NK, Batts DH. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003;51:1239-46.
8. Kutscha-Lissberg F, Hebler U, Muhr G, Koller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003;47:3964-6.
9. Lovering AM, Zhang J, Bannister GC, Lankester BJA, Brown JHM, Narendra G, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002;50:73-7.
10. MacGowan AP. Pharmacokinetic and pharmacodynamic profiles of line-zolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother 2003;51(suppl 2):17-25.
11. Baddour LM. Recent considerations in recurrent cellulitis. Curr Infect Dis Rep 2001;3:461-5.
12. Stein GE, Schooley S, Kak V, Havlichek DH. Oral linezolid as alternative therapy in patients with cellulitis who have been referred to an infusion center. Pharm Ther 2004;29:510-1.
13. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis 1997;25:112-8.
14. Shaikh ZHA, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 2001;33:375-9.
15. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. Approved standard. Document no. M7-A5. Wayne, PA: National Committee for Clinical Laboratory Standards. 2000;20:10-4.
16. Methods for antimicrobial susceptibility testing of anaerobic bacteria. 5th ed. Approved standard. Document no. M11-A5. Wayne, PA: National Committee for Clinical Laboratory Standards. 2001.
17. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline. Document no. M26-A. Villanova, PA: National Committee for Clinical Laboratory Standards. 1999;19.
18. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 2003;51(suppl 2):9-16.
19. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135-42.
20. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004;38: 17-24.
21. Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000;44:3408-13.
22. Burkhardt O, Barner N, vonderHoh N, Koppe P, Pletz MW, Nord CE, et al. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J Antimicrob Chemother 2002; 50:707-12.
23. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003;47:548-53.
24. Moellering RC. A novel antimicrobial agent joins the battle against resistant bacteria. Ann Intern Med 1999;130:155-7.
25. Cha R, Akins RL, Rybak MJ. Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacokinetic model. Pharmacotherapy 2003;23:1531-7.
26. Cha R, Brown WJ, Rybak MJ. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2003;47: 3960-3.
27. Yagi BH, Zurenko GE. An in vitro time-kill assessment of linezolid and anaerobic bacteria. Anaerobe 2003;9:1-3.
28. Leggett JE, Craig WA. Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against gram-negative bacilli. Antimicrob Agents Chemother 1989;33:35-40.
29. Andes D, van Ogtrop ML, Peng J, Craig WA. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002;46:3484-9.
30. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use program. Clin Pharmacokinet 2003;42:1411-23.
31. Bosso JA, Flume PA, Gray SL. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2004;48:281-4.
32. Schaadt RD, Batts DH, Daley-Yates PT, Pawsey SD, Stalker DJ, Zurenko GE. Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidones aperezolid and linezolid. Diagn Microbiol Infect Dis 1997;28:201-4.
33. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis 2004;38:864-70.
34. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate use program. Clin Infect Dis 2003;36:159-68.
35. Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001;32:1373-5.
36. Till M, Wixson RL, Pertel PE. Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002;34: 1412-4.
37. Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 2004;32:8-14.